These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 23328025)

  • 1. [Cross-over studies].
    Bonten TN; Siegerink B; van der Bom JG
    Ned Tijdschr Geneeskd; 2013; 157(3):A5542. PubMed ID: 23328025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dog-leg: an alternative to a cross-over design for pragmatic clinical trials in relatively stable populations.
    Hooper R; Bourke L
    Int J Epidemiol; 2014 Jun; 43(3):930-6. PubMed ID: 24453236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sample size calculation for cluster randomized cross-over trials.
    Giraudeau B; Ravaud P; Donner A
    Stat Med; 2008 Nov; 27(27):5578-85. PubMed ID: 18646266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doubly randomized delayed-start design for enrichment studies with responders or nonresponders.
    Liu Q; Lim P; Singh J; Lewin D; Schwab B; Kent J
    J Biopharm Stat; 2012; 22(4):737-57. PubMed ID: 22651112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample sizes for clinical trials with normal data.
    Julious SA
    Stat Med; 2004 Jun; 23(12):1921-86. PubMed ID: 15195324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies.
    Woolley SB; Cardoni AA; Goethe JW
    Pharmacotherapy; 2009 Dec; 29(12):1408-16. PubMed ID: 19947800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and analysis of crossover trials for absorbing binary endpoints.
    Nason M; Follmann D
    Biometrics; 2010 Sep; 66(3):958-65. PubMed ID: 19930189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of studies of treatments for hand eczema-the EDEN hand eczema survey.
    Van Coevorden AM; Coenraads PJ; Svensson A; Bavinck JN; Diepgen TL; Naldi L; Elsner P; Williams HC;
    Br J Dermatol; 2004 Aug; 151(2):446-51. PubMed ID: 15327553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design paper: the DEMO trial: a randomized, parallel-group, observer-blinded clinical trial of aerobic versus non-aerobic versus relaxation training for patients with light to moderate depression.
    Krogh J; Petersen L; Timmermann M; Saltin B; Nordentoft M
    Contemp Clin Trials; 2007 Jan; 28(1):79-89. PubMed ID: 16935032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over.
    Curtin F; Elbourne D; Altman DG
    Stat Med; 2002 Aug; 21(15):2161-73. PubMed ID: 12210631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficiency of the cross-over design: an empirical estimation.
    Garcia R; Benet M; Arnau C; Cobo E
    Stat Med; 2004 Dec; 23(24):3773-80. PubMed ID: 15580599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal allocation of participants for the estimation of selection, preference and treatment effects in the two-stage randomised trial design.
    Walter SD; Turner RM; Macaskill P; McCaffery KJ; Irwig L
    Stat Med; 2012 Jun; 31(13):1307-22. PubMed ID: 22362374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The limits of controlled clinical studies: the case of rheumatology].
    Portioli I
    Ann Ital Med Int; 2000; 15(1):39-46. PubMed ID: 10842890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parallel, AA/BB, AB/BA and Balaam's design: efficient and maximin choices when testing the treatment effect in a mixed effects linear regression.
    Candel MJ
    Pharm Stat; 2012; 11(2):97-106. PubMed ID: 22337606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The N-of-1 trial: the ideal study design that is underused].
    Vandenbroucke JP
    Ned Tijdschr Tandheelkd; 2007 Jun; 114(6):260-2. PubMed ID: 17695213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CrossOver: an algorithm for the construction of efficient cross-over designs.
    John JA; Russell KG; Whitaker D
    Stat Med; 2004 Sep; 23(17):2645-58. PubMed ID: 15316948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The cluster-randomized trial].
    Giraudeau B
    Med Sci (Paris); 2004 Mar; 20(3):363-6. PubMed ID: 15067584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.